SLC18A2 and thanatophoric dysplasia: For example, in the treatment of tardive dyskinesia (TD) and other hyperkinetic movements, it may be beneficial to inhibit VMAT2 activity to reduce DA storage and release from pre-synaptic neurons into the synaptic cleft, reducing stimulation of post-synaptic DA receptors and subsequently decreasing dyskinetic movements.